Imaging Core

1.摘要（成像核心） 成像核心的总体目标是获得淀粉样蛋白PET和高口径MRI数据，以表征 斯坦福大学ADRC参与者沿着AD和PD谱;使这些数据可用于广泛的 研究人员在斯坦福大学;并提供培训的采集，解释和分析成像数据 与神经退行性疾病有关。利用斯坦福大学在脑成像方面的优势 和放射化学，将集中在淀粉样蛋白PET成像结合结构和 功能性磁共振成像，并使创新的探索新的PET目标。格雷丘斯博士，核心主任 有助于推进应用功能连接措施的研究AD。莫米诺医生， 成像核心的共同主任，为描述AD的临床前阶段做出了贡献， 淀粉样蛋白和tau PET。成像核心的第二个主要重点将是使采集的数据可用于 并且很容易被斯坦福大学的各个学科和学校的研究人员使用。成像核心将使用 RedTree基础设施，为研究人员提供PET（全球和区域）成像数据摘要 淀粉样蛋白和tau PET值），结构测量（区域灰质体积和厚度值），以及 静息状态功能测量（网络连接）。成像数据将与受试者的辅助 数据（包括神经心理学测量、脊髓液蛋白质、血浆蛋白质组学等）。这将允许 尽可能广泛的斯坦福大学研究人员，有或没有成像专业知识，使用 ADRC数据。大多数临床核心参与者的淀粉样蛋白PET和MRI数据的可用性将 大大提高了诊断的准确性，这将从根本上加强任何在 斯坦福大学ADRC。这些成像数据与来自生物标志物核心的生物流体数据一起， 根据AD的最新研究框架进行分类，以便斯坦福大学ADRC数据可以 更容易与其他中心的数据协调。

1. SUMMARY (Imaging Core) The overall goals of the Imaging Core are to obtain amyloid PET and high caliber MRI data to characterize Stanford ADRC participants along the AD and PD spectrums; to make these data available to a wide range of investigators at Stanford; and to provide training on the acquisition, interpretation, and analysis of imaging data relevant to neurodegenerative disease. The Imaging Core, capitalizing on Stanford's strength in brain imaging and radiochemistry, will focus on incorporation of amyloid PET imaging in conjunction with structural and functional MRI, and enable innovation for the exploration of novel PET targets. Dr. Greicius, the Core Director, has helped advance the application of functional connectivity measures to the study of AD. Dr. Mormino, the co-Director of the Imaging Core, has made contributions to characterizing the preclinical stage of AD using amyloid and tau PET. A second major focus of the Imaging Core will be to make the acquired data available to and readily used by researchers across disciplines and schools at Stanford. The Imaging Core will use the RedTree infrastructure to provide researchers with summary imaging data for PET (global and regional amyloid and tau PET values), structural measures (regional gray matter volume and thickness values), and resting state functional measures (network connectivity). The imaging data will be linked to subjects' ancillary data (including neuropsychological measures, spinal fluid proteins, plasma proteomics, etc.). This will allow the widest possible set of Stanford investigators, with or without imaging expertise, to test hypotheses using the ADRC data. The availability of amyloid PET and MRI data on the majority of clinical core participants will greatly enhance diagnostic accuracy which will fundamentally strengthen any clinical research undertaken at the Stanford ADRC. These imaging data, in conjunction with biofluid data from the Biomarker Core, will also enable classification according to the recent research framework of AD so that Stanford ADRC data can be more readily harmonized with data from other centers.